U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced So...(the Company's filings with the Securitie...),Health

Date:10/18/2007

the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

E: media@ctiseattle.com

http://www.cticseattle.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.cticseattle.com/investors.htm

'/>"/>

SOURCE Cell Therapeutics, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Radiation Overdose at the Beatson Oncology Centre
2. Videoconferencing, an impetus to Pediatric Oncology
3. Oncology Drug Pemnat Launched By NATCO
4. United Biotech Launches New Oncology Division
5. Bengal Teenager to Participate in World Oncology Camp
6. CMPMedica Adds Oncology Search Engine to SearchMedica.com
7. Bird Flu: Orissa Initiates Protective Measures
8. Biota Initiates Drug Testing War against Common Cold
9. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
10. Government Initiates A Program To Curb HIV
11. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2